Bone metastasis, also known as "bone mets", occurs when cancer cells break off from a primary tumor that is anywhere else in the body. These cancer cells travel through the blood stream, or lymph system, to a part of the bone and become metastatic cancer cells. This is dissimilar to a primary bone tumor, which normally starts in the bone. When these cancer cells deposit themselves into the bone, they release substances that turn on either osteoclasts or osteoblasts. Osteoclasts will lead to the breakdown of the bone, without a new bone being made, which weakens the bones.
Metastases can occur in any bone in the body, but are most often found in bones near the center of the body. Bones are the third most frequent site of metastases, behind lung and liver. Bone metastasis can occur in any bone, but occurs most commonly in the spine, pelvis, and thigh. Bone metastasis can cause pain and broken bones. The number of people with the bone metastases is rising every year. According to the American Cancer Society, in 2019, approximately 3,500 new cases of bone cancer are expected to be diagnose, and 1,660 deaths are expected to result from these cancers. One way or the other, progress in the treatment of bone metastases is being made through clinical trials. Clinical trials can involve the use of new medications or new methods of treatment. These clinical trials are helping to find the right treatment.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence